Update date
26 May 2026
YD Bio Ltd financial metrics
Period Q4 2025 · Filed 26 May 2026
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
70,789,261
Period-end balance · 31 Dec 2025
|
|
| Common Stock, Shares, Outstanding |
70,789,261
Period-end balance · 31 Dec 2025
|
+9.4% |
| Common Stock, Value, Issued |
$7,079
Period-end balance · 31 Dec 2025
|
+9.4% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$413,290
Period-end balance · 31 Dec 2025
|
+1438% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$167,477
Period-end balance · 31 Dec 2025
|
+93% |
| Accrued Liabilities, Current |
$403,445
Period-end balance · 31 Dec 2025
|
+166% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$213,936
Period-end balance · 31 Dec 2025
|
+375% |
| Assets |
$13,779,397
Period-end balance · 31 Dec 2025
|
+101% |
| Assets, Current |
$9,670,190
Period-end balance · 31 Dec 2025
|
+179% |
| Cash and Cash Equivalents, at Carrying Value |
$6,007,615
Period-end balance · 31 Dec 2025
|
+92% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$6,007,615
Period-end balance · 31 Dec 2025
|
+92% |
| Common Stock, Par or Stated Value Per Share |
0.0001
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares Authorized |
500,000,000
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares, Issued |
70,789,261
Period-end balance · 31 Dec 2025
|
+9.4% |
| Contract with Customer, Liability, Current |
$30,153
Period-end balance · 31 Dec 2025
|
+9.4% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$551,303
Period-end balance · 31 Dec 2025
|
+229% |
| Deferred Tax Assets, Valuation Allowance |
$552,846
Period-end balance · 31 Dec 2025
|
+227% |
| Intangible Assets, Net (Excluding Goodwill) |
$2,609,739
Period-end balance · 31 Dec 2025
|
-2.6% |
| Inventory, Net |
$1,879,542
Period-end balance · 31 Dec 2025
|
+4934% |
| Lessee, Operating Lease, Liability, to be Paid |
$6,764
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$6,824
Period-end balance · 31 Dec 2025
|
|
| Liabilities |
$16,635,060
Period-end balance · 31 Dec 2025
|
+5972% |
| Liabilities and Equity |
$13,779,397
Period-end balance · 31 Dec 2025
|
+101% |
| Liabilities, Current |
$1,643,578
Period-end balance · 31 Dec 2025
|
+525% |
| Long-term Debt and Lease Obligation |
$6,764
Period-end balance · 31 Dec 2025
|
|
| Operating Lease, Liability |
$6,764
Period-end balance · 31 Dec 2025
|
-70% |
| Operating Lease, Liability, Current |
$6,764
Period-end balance · 31 Dec 2025
|
-59% |
| Operating Lease, Right-of-Use Asset |
$8,470
Period-end balance · 31 Dec 2025
|
-64% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0422
Period-end balance · 31 Dec 2025
|
|
| Property, Plant and Equipment, Gross |
$87,916
Period-end balance · 31 Dec 2025
|
+7.5% |
| Property, Plant and Equipment, Net |
$59,340
Period-end balance · 31 Dec 2025
|
-7.8% |
| Retained Earnings (Accumulated Deficit) |
-$10,238,359
Period-end balance · 31 Dec 2025
|
-431% |
| Stockholders' Equity Attributable to Parent |
-$2,855,663
Period-end balance · 31 Dec 2025
|
-143% |
Comparisons, sources and research notes
Sources and sharing
YDES - YD Bio Ltd Financial Facts
- Context
- Latest metrics period: Q4 2025
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for YDES - YD Bio Ltd
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 26 May 2026.
Filing notes and source
Key facts
- YDES - YD Bio Ltd financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q4 2025.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Fair value per share
n/a
Market price
$7.42
YDES - Local security
PEG ratio
n/a
Enterprise value
-$117.04M
Equity value
n/a
DCF fair value scenarios
Bear
n/a
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
n/a
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
n/a
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
829.5x
Local security market cap / SEC revenue
P/B
n/a
Local security market cap / SEC equity
Equity is unavailable or not positive
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- -$8.04M
- Trailing SEC FCF
- Reported FCF
- -$8.04M
- Net income
- -$8.31M
- EBITDA
- -$5.26M
- Cash
- $6.01M
- Debt
- n/a
- Equity
- -$2.86M
- Shares
- 66,719,177
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -6,596,706.0 USD · through 2025-12-31 · reported annual SEC source
- Capital expenditures: 1,440,019.0 USD · through 2025-12-31 · reported annual SEC source
- Cash and equivalents: 6,007,615.0 USD · through 2025-12-31 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Debt unavailable: no complete usd debt balance at the latest balance date
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Debt missing: equity value and market ev unavailable
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first